Volume 21, Issue 1 (Iranian South Medical Journal 2018)                   Iran South Med J 2018, 21(1): 19-28 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zaker Hosseini M, Naeimi S, Moradinasab M, Taherkhani S, Farshadpour F, Ansarifar A et al . Codon 72 Polymorphism of TP53 Gene in Cervical Biopsies with Abnormal Histology in Bushehr Province. Iran South Med J 2018; 21 (1) :19-28
URL: http://ismj.bpums.ac.ir/article-1-911-en.html
1- Department of Genetics, Colleague of Science, Kazerun branch, Islamic Azad University, Kazerun, Iran
2- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
3- Reproductive Health and Midwifery Department, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran
4- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
5- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , taherkhanireza2005@yahoo.com
Abstract:   (5264 Views)
Background: TP53 tumor suppressor gene plays a role in repairing DNA damage as well as in cell apoptosis. This study was conducted to compare codon 72 polymorphism of TP53 gene between abnormal cervical tissue samples and samples of healthy women as a control group. In addition the frequency of human herpes simplex viruses (HSV) in these samples was determined.
Material and Methods: In this case-control study, 110 biopsies of the cervix with abnormal pathology were examined from archives of the Department of Pathology at Shohadaye Khalij Fars Hospital, and 164 healthy women were selected as the control group. PCR test was used for detection of HSV, and Allele-specific PCR was used for analyzing codon 72 polymorphism of TP53 gene. Data was analyzed in SPSS software.
Results: Distribution of codon 72 of TP53 genotypes in patient and control groups was not statistically significant. Evaluation of the frequency of arginine and proline alleles in the patient and control groups revealed that fewer patients were without proline allele (19%) compared to the control (30.1%), and this difference was statistically significant (p=0.04), (OR: 1.03-3.36، CI 95%=1.86). Furthermore, there was no significant correlation between TP53 genotype and variables of the pathology report, age, ethnicity and place of residence. In this study, HSV was not detected in the samples.
Conclusion: Because of the significant difference in proline allele between the case and control groups, it appears that this allele is associated with the abnormal cervical pathology results in Bushehr Province.
Full-Text [PDF 758 kb]   (1807 Downloads)    
Type of Study: Original | Subject: Biochemistry. Cell Biology and Genetics
Received: 2017/03/29 | Accepted: 2017/11/11 | Published: 2018/02/26

1. Sankaranarayanan R, Thara S, Esmy PO, et al. Cervical cancer: screening and therapeutic perspectives. Medical Principles and Practice 2008;17(5):351-64. [DOI:10.1159/000141498]
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer 2013;49(6):1374-403. [DOI:10.1016/j.ejca.2012.12.027]
3. Khan SA, Thomas HC, Toledano MB, et al. p53 Mutations in human cholangiocarcinoma: a review. Liver international 2005; 25(4): 704-16. [DOI:10.1111/j.1478-3231.2005.01106.x]
4. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: twenty five years understanding the mechanism of genome protection. Journal of physiology and biochemistry 2004; 60(4):287-307. [DOI:10.1007/BF03167075]
5. Pietsch E, Humbey O, Murphy M. Polymorphisms in the p53 pathway. Oncogene 2006; 25(11):1602-11. [DOI:10.1038/sj.onc.1209367]
6. Murphy M. Polymorphic variants in the p53 pathway. Cell Death & Differentiation 2006;13(6):916-20. [DOI:10.1038/sj.cdd.4401907]
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 16; 408(6810): 307-10. [DOI:10.1038/35042675]
8. Karki R, Pandya D, Elston RC, et al. Defining "mutation" and "polymorphism" in the era of personal genomics. BMC Medical Genomics 2015; 8:37. [DOI:10.1186/s12920-015-0115-z]
9. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000; 9(10):1037-42.
10. Noma C, Miyoshi Y, Taguchi T, et al. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer letters 2004; 210(2):197-203. [DOI:10.1016/j.canlet.2004.03.031]
11. Pérez LO, Abba MC, Dulout FN, Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in LaPlata, Argentina. World J Gastroenterol 2006; 12(9):1426-9. [DOI:10.3748/wjg.v12.i9.1426]
12. Trifa F, Karray-Chouayekh S, Mabrouk I, et al. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer epidemiology 2010; 34(2): 184-8. [DOI:10.1016/j.canep.2010.02.007]
13. Dumont P, Leu JI, Della Pietra AC, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature genetics 2003; 33(3):357-65. [DOI:10.1038/ng1093]
14. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90: 1-6.
15. Ermel AC, Brown DR. Viral Infections. In: Kasper DL, Fauci AS, editors. Harrison's Infectious Diseases. 3rd ed. New York: The McGraw-Hill Companies, 2017, 768-73.
16. Miller S. Human Tumour Viruses. In: Carroll KC, Butel JS, Morse SA, Mietzner TA, editors. Jawetz, Melnick, & Adelberg's Medical Microbiology. 27th ed. New York: McGraw-Hill Education, 2016, 619-39.
17. Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clinical microbiology reviews 1995; 8(4): 549-56. [DOI:10.1128/CMR.8.4.549]
18. Alibek K, Baiken Y, Kakpenova A, et al. Implication of human herpesviruses in oncogenesis through immune evasion and supression. Infectious agents and cancer 2014; 9(3):1-8. [DOI:10.1186/1750-9378-9-3]
19. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 1998; 393(6682):229-34. [DOI:10.1038/30400]
20. Lattuada D, Vigano P, Somigliana E, et al. Analysis of the codon 72 polymorphism of the TP53 gene in patients with endometriosis. Molecular human reproduction 2004;10(9):651-4. [DOI:10.1093/molehr/gah093]
21. Read SJ, Kurtz JB. Laboratory diagnosis of common viral infections of the central nervous system by using a single multiplex PCR screening assay. Journal of clinical microbiology 1999;37(5):1352-5. [DOI:10.1128/JCM.37.5.1352-1355.1999]
22. Taherkhani R, Farshadpour F, Makvandi M, et al. Determination of Cytomegalovirus Prevalence and Glycoprotein B Genotypes Among Ulcerative Colitis Patients in Ahvaz, Iran. Jundishapur journal of microbiology 2015;8(2):e17458. [DOI:10.5812/jjm.17458]
23. Beckman G, Birgander R, Själander A, et al. Is p53 polymorphism maintained by natural selection? Human heredity 1994;44(5):266-70. [DOI:10.1159/000154228]
24. Omori S, Yoshida S, Kennedy SH, et al. Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. Journal of the Society for Gynecologic Investigation 2004;11(4):232-6. [DOI:10.1016/j.jsgi.2003.11.004]
25. Pillai RM, Sreevidya S, Pollock BH, Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. Journal of cancer research and clinical oncology 2002;128(11):627-31. [DOI:10.1007/s00432-002-0383-9]
26. Kouamou V, Chin'ombe N, Matimba A, Ket al. P53 Codon 72 Polymorphism and the Risk of Cervical Cancer in Zimbabwean Women. International Journal of TROPICAL DISEASE & Health 2016;15(3):1-6. [DOI:10.9734/IJTDH/2016/24676]
27. Basyar R, Saleh AZ, Sastradinata I, et al. p53 Gene Codon 72 Polymorphisms among Cervical Carcinoma Patients. Indonesian Journal of Obstetrics and Gynecology 2015; 3(3):165-9. [DOI:10.32771/inajog.v3i3.48]
28. Assoumou SZ, Boumba ALM, Ndjoyi-Mbiguino A, et al. The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. Medical Oncology 2015;32(1):281. [DOI:10.1007/s12032-014-0281-4]
29. Malisic E, Jankovic R, Brotto K, Radulovic S. TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women. Archives of gynecology and obstetrics 2013; 288(3):621-5. [DOI:10.1007/s00404-013-2783-2]
30. Li B, Wang X, Chen H, et al. TP53 codon 72 polymorphism and susceptibility to cervical cancer in the Chinese population: an update meta-analysis. International journal of clinical and experimental medicine 2015;8(6):9055-62.
31. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-37. [DOI:10.1038/sj.onc.1207428]
32. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. International journal of cancer 2004; 108(2): 196-9 [DOI:10.1002/ijc.11548]
33. Bergamaschi D, Samuels Y, Sullivan A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nature genetics 2006; 38(10):1133-41. [DOI:10.1038/ng1879]
34. Shanehsazzadeh M, Sharifi-Rad J, Behbahani M, et al. Analysis of Human Papillomavirus and Herpes Simplex Virus Genus-2 from Patients with Cervical Cancer in Isfahan, Iran. Mater Sociomed 2014; 26(4): 234-6. [DOI:10.5455/msm.2014.26.234-236]

Send email to the article author

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian South Medical Journal

Designed & Developed by: Yektaweb